

1 **Medication use reported by individuals with tinnitus who are**
2 **seeking internet-based psychological interventions**

3

4 **Vinaya Manchaiah,^{1,2} Alicia Brazelton,³ Hansapani Rodrigo,⁴ Eldré W. Beukes,^{1,5} Marc A.**
5 **Fagelson,^{6,7} Gerhard Andersson,^{8,9} & Meghana V. Trivedi³**

6

7 1. Department of Speech and Hearing Sciences, Lamar University, Beaumont, Texas, USA

8 2. Department of Speech and Hearing, School of Allied Health Sciences, Manipal,
9 Karnataka, India

10 3. Department of Pharmacy Practice and Translational Research, University of Houston
11 College of Pharmacy, Houston, Texas, USA

12 4. School of Mathematical and Statistical Sciences, University of Texas Rio Grande Valley,
13 Texas USA

14 5. Vision and Hearing Sciences Research Group, School of Psychology and Sport Science,
15 Anglia Ruskin University, Cambridge, United Kingdom

16 6. Department of Audiology and Speech-Language Pathology, East Tennessee State
17 University, Johnson City, Tennessee, USA

18 7. Audiologic Rehabilitation Laboratory, Auditory Vestibular Research Enhancement
19 Award Program, Veterans Affairs Medical Center, Mountain Home, Tennessee, USA

20 8. Department of Behavioral Sciences and Learning, Department of Biomedical and Clinical
21 Sciences, Linköping University, Linköping, Sweden

22 9. Department of Clinical Neuroscience, Division of Psychiatry, Karolinska Institute,
23 Stockholm, Sweden

24

25 **Corresponding author:** Dr. Vinaya Manchaiah

26 **Communication address:** Department of Speech and Hearing Sciences,
27 Lamar University, Beaumont, Texas 77710, USA

28 **Email:** vinaya.manchaiah@lamar.edu

29 **Tel:** +1 (409) 880 8927

30 **Fax:** +1 (409) 880 2265

31

32 **Abstract**

33 **Purpose:** The study examined medication use by individuals with tinnitus who were seeking
34 help for their tinnitus by means of a psychological intervention.

35 **Method:** The study used a cross-sectional survey design and included individuals with tinnitus
36 enrolled in an Internet-based cognitive behavioral therapy (ICBT) trial (n = 439). Study
37 participants provided demographic details, completed various structured questionnaires as well
38 as provided details about the medications used. The self-reported medications were classified
39 using the USP Medicare Model Guidelines v7.0.

40 **Results:** Current medication use was reported by 67% (n = 293) of the study participants. Those
41 currently using medication were older, had consulted their primary care physician, had greater
42 tinnitus severity, depression, anxiety, and insomnia when compared with those not reporting any
43 current medication use. The top 10 medication used included: cardiovascular agents (n = 162;
44 55.3%), antidepressants (n = 80; 27.3%), electrolytes/minerals/metals/vitamins (n = 70; 23.9%),
45 respiratory tract/pulmonary agents (n = 62; 21.2%), anxiolytics (n = 59; 20.1%), hormonal
46 agents/stimulant/replacement/modifying (thyroid) (n = 45; 15.4%), gastrointestinal agents (n =
47 43; 14.7%), analgesics (n = 33; 11.3%), blood glucose regulators (n = 32; 10.9%), and
48 anticonvulsants (n = 26; 8.87%). Some associations between type of medication used and
49 demographic/ tinnitus-related variables were noted especially for the cardiovascular agents,
50 electrolytes/minerals/metals/vitamins, and anxiolytics.

51 **Conclusions:** This exploratory study indicated a large percentage of patients using medication
52 and a range of medications. Further studies are required to assess the effects of such medications
53 on the tinnitus percept and if concurrent medication moderate treatment effects.

54

55 **Key Words**

56 Tinnitus, Medication use, Supportive care medications, Internet-intervention

57 **Introduction**

58 Tinnitus is the perception of sound in the absence of a corresponding external sound source. It is
59 a prevalent condition, experienced by 10-15% of adults in the general population (McCormack et
60 al., 2016), although approximately 1-2% of the population are severely affected (Bhatt et al.,
61 2016; Davis & Refaie, 2002). Those with tinnitus report various associated difficulties including
62 problems with attention and concentration, increased anxiety and depression, insomnia, and
63 reduced general health-related quality of life (HRQoL) (e.g., Salazar et al., 2020)

64
65 Various non-auditory factors including levels of stress, emotional state, mood, life events and
66 general health could mediate the tinnitus perception and its effects on the individual (Andersson
67 & Westin, 2008; Beukes et al., 2020), although the associations between all these factors and
68 tinnitus perception and its consequences remain topics requiring further investigation. While
69 some of these factors can affect tinnitus perceptions in terms of the types and loudness of sounds
70 heard, their influence on the distress associated with tinnitus produce substantial challenges for
71 many patients. Various forms of help-seeking may be demonstrated by patients during these
72 times, including internet searches, trying sound enrichment applications, or the use of prescribed
73 or over-the-counter (self-selected) medication. For example, the use of antidepressants for the
74 treatment of tinnitus is common (e.g., Baldo et al., 2012), and medications are often prescribed
75 or taken to address associated difficulties such as sleep problems (e.g., Lie et al., 2015).

76 Although numerous pharmacological compounds have been tested with the aim to eliminate
77 tinnitus, (Langguth et al., 2019). other investigators have identified ototoxic agents causing
78 and/or exacerbating tinnitus (for review see Ganesan et al., 2018; Rizk et al., 2020).

79

80 There remains, however, a limited understanding of the medications used by individuals with
81 tinnitus in general, and the effect of these medications on patients' perception of tinnitus in
82 particular. Patients and research participants often report anecdotal observations regarding how
83 certain medications or supplements have a positive or negative effect on their tinnitus. Further
84 investigations regarding these reports may be useful for several reasons: Firstly, interviewing
85 patients may provide information regarding the potential effects on tinnitus of their general
86 health (Qato et al., 2008, 2016). Secondly, insights may be gained regarding the use of
87 medication for tinnitus-related problems such as insomnia (Cronlein et al., 2011). Thirdly, such
88 questioning will provide patients the opportunity to specify the use of ototoxic medications that
89 may influence their hearing as well as tinnitus perception, as well as to identify positive and/or
90 adverse effects, and potential drug interactions.

91
92 Long-term medication usage can be assessed by either examining the medical records and/or
93 using patient self-report methods. While the accuracy of these two methods may vary, research
94 studies often use self-report methods to examine medication use (West et al., 1995). Large
95 clinical studies have generally found agreement between self-reported medication compared with
96 pharmacy records, especially for stable long-term medications (Drieling et al., 2016; Fujita et al.,
97 2015). The value self-report was demonstrated in a recent study using self-reported outcomes to
98 examine the use of medication by treatment-naïve lung cancer patients identifying the need for
99 better screening for pain and depression in this population (Hoang et al., 2020).

100
101 Due to the lack of robust studies regarding the effects of medication on tinnitus, the aim of the
102 current exploratory study was to examine the use of medication by individuals with tinnitus who

103 were enrolled in a psychological intervention study. The specific questions included: (a) Is there
104 a difference in demographic and/or tinnitus related variables in individuals with tinnitus based on
105 the duration and frequency of medication use, (b) What are the most common medications used
106 by individuals with tinnitus? and (c) Is there an association between the type of medication used
107 and demographic and/or tinnitus related variables?

108

109 **Method**

110 **Study Design**

111 This exploratory study used a cross-sectional survey design. Individuals with tinnitus who were
112 enrolled for Internet-based cognitive behavioral therapy (ICBT) trials (Clinical Trials.gov
113 registration numbers NCT04004260, NCT04335812, and NCT04335929) were included
114 (Beukes, Aronson, Andersson, et al., In press; Beukes, Andersson, Fagelson, et al., In press;
115 Beukes et al., 2021c; Manchaiah et al., 2020). Of the 440 people who initiated the registration,
116 one did not complete the questionnaire and was removed; the remaining 439 participants were
117 included. Ethical approval (IRB-FY17-209, IRB-FY20-200-1, and IRB-FY20-200-2) was
118 obtained from the Institutional Review Board at Lamar University, Beaumont, Texas, United
119 States.

120

121 **Data Collection**

122 The data were collected using a web-based questionnaire which included questions about (a)
123 demographical factors (e.g., age, gender, education, work status), (b) tinnitus-related variables
124 that were assessed using general questions (e.g., duration of tinnitus) as well as standardized
125 questionnaires, and (c) medication use. The standardized questionnaires assessed the tinnitus

126 severity using the Tinnitus Functional Index (TFI; Meikle et al., 2012), anxiety using the
127 Generalized Anxiety Disorder – 7 (GAD7; Spitzer et al., 2006), depression using the Patient
128 Health Questionnaire – 9 (PHQ-9; Kroenke et al., 2011), insomnia using the Insomnia Severity
129 Index (ISI; Bastien et al., 2001), and the HRQoL using the EQ-5D-5L VAS scale (Rabin & de
130 Charro, 2001). Medication use was assessed using an open-ended question worded as: Please list
131 any medications you currently take (select none or list them). Although this study relied on self-
132 reported data, the questioning was shown to be a reliable method in previous studies (Drieling et
133 al., 2016; Fujita et al., 2015). Furthermore, most patients apparently completed the questionnaire
134 online while at home, thus participants had access to their medications to crosscheck when
135 answering such questions.

136

137 If the participants reported any medication, they were categorized as “medication use” group.
138 Those who did not report *any* medication were classified as “non-medication use” group. Also,
139 perceived effect of medication was examined using the question: What effects do these
140 medications have on your tinnitus? Response options included: no effect, improves my tinnitus,
141 or worsens my tinnitus.

142

143 **Medication Classification**

144 The self-reported medications were classified into various categories using the United States
145 Pharmacopeial Convention (USP) Medicare Model Guidelines v7.0, 2017 (United States
146 Pharmacopeial Convention, 2017). This classification has 48 categories and 154 classes. For the
147 purpose of this study, both the prescription and over-the-counter medications were first classified
148 for classes and then grouped in various categories. Individual components were categorized into

149 separate classes for drug products containing two or more active ingredients. Vitamins and other
150 supplements were categorized in the electrolytes/minerals/metals/vitamins category. A licensed
151 pharmacist (AB) performed the classification of medication and queries were resolved by
152 another licensed pharmacist and Associate Professor of Clinical Pharmacy and Pharmacology
153 (MVT).

154

155 **Data Analysis**

156 Data were analyzed using the R software Psych package. Chi square or Fisher's exact test were
157 used to study the association between medication use and demographics/tinnitus related
158 variables. Two sample *t*-test or Mann Whitney *U* test were used to study the difference in
159 demographic or tinnitus related variables based on medication use. In addition, logistic
160 regression was used to study the effect of tinnitus-related variables on medication use,
161 controlling for the participant demographic characteristics.

162

163 **Results**

164 **Effect of Medication Use**

165 Of the 439 participants enrolled in the study, 293 (66.7%) indicated the use of any medication
166 (assigned to the medication group), whereas the remaining 146 (33.3%) were assigned to the
167 non-medication group.

168

169 For the overall sample ($n = 439$), when responding to the question what effects the medications have
170 on tinnitus, 69% ($n = 303$) reported no effect, 6.8% ($n = 30$) reported it improved their tinnitus, 4.3%
171 ($n = 19$) reported that it worsened their tinnitus, and the remaining 19.8% ($n = 87$) did not answer the

172 question. For those from the overall sample who reported using medication (n=293), when
173 responding to the question what effects the medications have on tinnitus, 84.3% (n = 247)
174 reported no effect, 9.6% (n = 28) reported that it improved their tinnitus, and 6.1% (n = 18)
175 reported that it worsened their tinnitus. Fisher's Exact test suggested no association ($p = .12$)
176 between perceived effect of medication on tinnitus across the groups.

177

178 **Association Between Medication Use and Demographic/Tinnitus-Related Variables**

179 Table 1 presents the relationship between demographic variables and medication use. The
180 medication group (mean age of 56.1 years) was significantly older ($p < .001$) when compared to
181 the non-medication group (mean age of 51.1 years). Those who consulted their Primary Care
182 Physicians (PCP) had 1.99 times higher odds of using medications ($p < .001$). None of the other
183 demographic variables showed a significant association with the medication use.

184

185 **Table 1: Relationship between demographic variables and medication use. All categorical**
186 **variables were analyzed with either Chi square or Fishers exact tests and corresponding,**
187 **Unadjusted odds ratio, and significance (p -value) are provided. All continuous**
188 **measurements were summarized with their Mean \pm SD and analyzed with two sample t -test/
189 **Mann Whitney U test are provided.****

190

Patient Characteristics	All subjects [n = 439]	Medication group (%) [n = 293]	Non medication group (%) [n = 146]	Unadjusted Odds Ratio (95% CI)	P-value
Age (in years)	54.4 ± 13.6	56.1 ± 12.9	51.1 ± 14.3		< .001
Duration of tinnitus (in years)	12.1 ± 13.0	12.6 ± 13.4	11.0 ± 12.3		.13
Gender					.17
Male	211 (48.06%)	134 (45.73%)	77 (52.74%)	Reference	
Female	228 (51.94%)	159 (54.27%)	69 (47.26%)	1.32 (0.89, 1.97)	
Work Type					.09
Entry level	15 (3.417%)	9 (3.072%)	6 (4.11%)	Reference	
Skilled professional	263 (59.91%)	165 (56.31%)	98 (67.12%)	1.12 (0.39,3.25)	
Retired	126 (28.70%)	95 (32.42%)	31 (21.23%)	2.04 (0.67, 6.19)	
Not working	35 (7.97%)	24 (8.19%)	11 (7.53%)	1.46 (0.41, 5.11)	
Schooling					
Less than high	5 (1.14%)	4 (1.37%)	1 (0.69%)	Reference	

High school	46 (10.48%)	28 (9.56%)	18 (12.33%)	0.29 (0.07, 3.57)	.74
Some college	129 (29.39%)	85 (29.01%)	44 (30.14%)	0.578 (0.66, 0.51)	
University	259 (58.99%)	176 (60.07%)	83 (56.85%)	0.64 (1.0, 0.57)	
Ethnicity					.20
Hispanic	90 (20.50%)	55 (18.77%)	35 (23.97%)	Reference	
Non-Hispanic	349 (79.49%)	238 (81.23%)	111 (76.03%)	1.365 (0.84, 2.21)	
Race					.06
American Indian	4 (0.91%)	3 (1.02%)	1 (0.69%)	Reference	
Asian	9 (2.05%)	3 (1.02%)	6 (4.11%)	0.11 (0.02, 2.33)	
Native Hawaiian	1 (0.228%)	1 (0.341%)	0 (0.000%)	0.25 (0.03, 53.51)	
Black	9 (2.05%)	8 (2.73%)	1(0.69%)	1.0 (0.18, 32.14)	
White	389 (88.61%)	264 (90.10%)	125 (85.62%)	0.524 (0.13, 6.19)	
More than one	27 (6.15%)	14 (4.78%)	27 (8.90%)	0.250 (0.06, 3.58)	
Consulted Primary Care Physician (PCP)					< .001
No	221 (50.34%)	131 (44.71%)	90 (60.64%)	Reference	

Yes	218 (49.66%)	162 (55.29%)	56 (38.36%)	1.99 (1.33, 2.98)	
-----	-----------------	-----------------	-------------	-------------------	--

191

192

193 Table 2 presents the relationship between tinnitus-related variables and medication use groups

194 examined using the Mann Whitney U test. The medication group had significantly higher tinnitus

195 severity, anxiety, depression, and insomnia, compared with those who did not use medications.

196 There was no difference between the groups for the general HRQoL. Furthermore, logistic

197 regression was used to examine the relationship between tinnitus-related variables and

198 medication use controlling for participants' demographic variables (i.e., age, gender, race, and

199 ethnicity). As per the likelihood ratio test, tinnitus severity ($p = 0.92$), anxiety ($p = 0.71$), and

200 depression ($p = 0.12$) and insomnia (0.38) were not significantly associated with medication use.

201

202

203 **Table 2: Tinnitus severity, anxiety, depression, insomnia and general health-related quality**
 204 **of life between medication and non-medication groups. Mean, Standard deviation and**
 205 **significance (*p*-value) based on Mann Whitney U test are provided.**

206

Patient Characteristics	Mean \pm SD			<i>p</i> -value
	All subjects [n = 439]	Medication [n = 293]	Non- medication [n = 146]	
Tinnitus severity (TFI)	52.5 \pm 21.7	54.5 \pm 21.9	48.4 \pm 20.8	.0078
Anxiety (GAD7)	7.24 \pm 5.68	7.71 \pm 5.79	6.26 \pm 5.35	.012
Depression (PHQ9)	7.38 \pm 5.95	8.06 \pm 6.20	5.97 \pm 5.14	.001
Insomnia (ISI)	11.3 \pm 6.74	12.0 \pm 6.74	9.82 \pm 6.54	.0015
General health-related quality of life (EQ-5D-5L VAS)	74.2 \pm 15.9	74.0 \pm 15.7	74.6 \pm 16.3	.5930


207

208

209 **Commonly Used Medications by Individuals with Tinnitus**

210 Medication use was reported for 27 of the 48 UPS categories in the Medicare Model Guidelines
 211 v7.0, although frequency of use was less than 5% in 14 of these categories (see Figure 1). The
 212 top 10 medications were used by at least 9% of those from the medication group, including:
 213 cardiovascular agents (n = 162; 55.3%), antidepressants (n = 80; 27.3%),
 214 electrolytes/minerals/metals/vitamins (n=70; 23.9%), respiratory tract/ pulmonary agents (n=62;

215 21.2%), anxiolytics (n = 59; 20.1%), hormonal agents, stimulant/ replacement/ modifying
 216 (thyroid) (n = 45; 15.4%), gastrointestinal agents (n = 43; 14.7%), analgesics (n = 33; 11.3%),
 217 blood glucose regulators (n = 32; 10.9%) and anticonvulsants (n = 26; 8.87%).
 218



219
 220 **Figure 1: Percentage of participants reporting various medications arranged in ascending**
 221 **order of the usage**

222 Association Between Type of Medication and Demographic/Tinnitus-Related Variables

224 Table 3 presents the relationship between type of medication used and demographic as well as
 225 tinnitus-related variables for the top 5 most frequently used medications. The variables, work
 226 type ($p < .001$), ethnicity ($p = .006$) and perceived medication effect ($p = .003$) showed a

227 significant relationship with the use of cardiovascular medication. The unadjusted odds ratio for
228 the use of cardiovascular medication was 2.56 times higher for retirees compared with those
229 whose work was regarded entry level. Non-Hispanic medication users had 2.31 times higher
230 odds of using cardiovascular medications compared to the Hispanics. Those who used
231 cardiovascular agents were significantly older ($p < .001$), had longer duration of tinnitus ($p =$
232 0.045), lower anxiety ($p = .001$), and lower depression ($p = .013$) than those who did not report
233 using these medications.

234
235 Participants who used antidepressants had significantly higher self-reported anxiety ($p = .019$)
236 and depression ($p < .001$) scores from the GAD7 and PHQ-9 questionnaires, respectively. The
237 variables gender ($p = 0.013$), education ($p = 0.0047$), ethnicity ($p = 0.04$), and perceived effect of
238 medication on tinnitus ($p = .017$) has a significant association with the use of
239 electrolytes/minerals/metals/vitamins. Females had a 2.03 times higher odds for using the
240 electrolytes/minerals/metals/vitamins, whereas individuals with college education (OR 0.09) and
241 non-Hispanic (OR 0.5) were at lower odds of electrolytes/minerals/metals/vitamins use.

242
243 The variables gender ($p = .016$) and ethnicity ($p = .04$) have significant association with the
244 respiratory tract/ pulmonary agents medication use, with females (OR 2.05) and non-Hispanic
245 (OR 2.5) having a higher odds of using this medication. The variable perceived medication
246 benefit ($p < .001$) had a significant association with anxiolytics, with those reporting medication
247 use improves their tinnitus were at a 5.1 times higher odds of using this class of medication.
248 Those reporting the use of anxiolytics also had higher tinnitus severity ($p < .001$), anxiety ($p <$
249 $.001$), depression ($p = .002$), and insomnia ($p = .003$).

250

251 **Table 3: Relation between type of medication used and demographic as well as tinnitus-**252 **related variables. Significance (* = $p < 0.05$; ** = $p < 0.01$) based on the Chi square test,**253 **Fishers exact test, or either two sample t -test/ Mann Whitney U test are provided.**

254

Demographic and tinnitus- related factors	Medication categories				
	Cardiovascular agents	Antidepressants	Electrolyte	Respiratory tract/ Pulmonary agents	Anxiolytics
Age	**				
Duration of tinnitus	*				*
Gender			*	*	
Work type	**				
Education			**		
Ethnicity	**		*	*	
Race					
Consulted PCP					
Hearing loss					
Perceived effect of medication on tinnitus	**		*		**

Tinnitus severity (TFI)					**
Anxiety (GAD7)	**	*			**
Depression (PHQ-9)	*	**			**
Insomnia (ISI)					**
General health-related quality of life (EQ-5D-5L VAS)					**

255

256

257 **Discussion**

258 The current study examined medication use by individuals with tinnitus who were participants in
 259 a treatment trial. As tinnitus is often associated with comorbidities such as anxiety, depression,
 260 and insomnia, the use of medication is not uncommon amongst individuals with tinnitus.

261 However, the usage and effects of such medications on tinnitus remain areas of speculation and
 262 investigation. The objective of the current study was to examine the types, numbers, and effects
 263 of medications used by individuals with tinnitus who are seeking psychological intervention. The
 264 key findings are discussed below.

265

266 Two thirds (67%) of the current study participants reported using some kind of medication.
267 When comparing those that used and did not use medication, participants reporting medication
268 use were significantly older than those who denied use. These results are comparable with the
269 findings from the general US population, as 46% of participants, and 85% of those of 60 years
270 and over, indicated they used drugs when questioned regarding drug use during the past 30 days
271 (Martin et al., 2019). The average age of participants in the current study was 54 years,
272 suggesting that while the medication use in tinnitus population in the US is comparable to
273 general population, the percentage of patients reporting use could vary depending on the age
274 group studied.

275

276 Those using medication had not shown significantly higher scores on indices related to tinnitus
277 severity, depression, anxiety, and insomnia when compared to those who did not report any
278 current medication use after adjusting for demographic variables (i.e., age, gender, race, and
279 ethnicity). We anticipated that those with higher medication use will have higher anxiety and
280 depression, as medication's intent would be to address these problems. However, this was not
281 observed in the current study. Further, these conditions psychological are often associated with
282 other physical health problems and long-term chronic diseases (Trick et al., 2016), hence their
283 potential to influence tinnitus effects. However, this association with tinnitus severity and
284 medication use was also not observed after adjusting for demographic variables. As anticipated,
285 individuals who had consulted their PCP for tinnitus, had significantly higher medication usage.
286 Nevertheless, these associations need further exploration in follow-up studies.

287

288 In the study, cardiovascular agents (beta-blockers and lipid lowering drugs), antidepressants,
289 electrolytes/minerals/metals/vitamins, respiratory tract/ pulmonary agents, and anxiolytics were
290 the most commonly used drugs. This is comparable to reports of lipid lowering (high cholesterol)
291 drugs, beta-blockers and antidiabetic drugs being the most commonly used drugs in US adults
292 over the age of 60 years, whereas antidepressants, analgesics (pain relief) and lipid lowering
293 drugs were among the most commonly used among adults aged 20-59 years (Martin et al., 2019).
294 Similarly, our findings of common use of electrolytes/minerals/metals/vitamins reflected the
295 common use of vitamins and dietary supplements by U.S. adults in previous reports (Rock et al.,
296 2007; Kantor et al., 2016). As the use of respiratory track/pulmonary agents was more common
297 in children and younger adults (Martin et al., 2019), higher use of these agents was surprising in
298 the current study focused on individuals with tinnitus. Among various respiratory tract/
299 pulmonary agents, the use of antihistamines was highest in our population. Recent studies show a
300 link between allergic rhinitis and eustachian tube dysfunction (reviewed in Juszczak and Loftus,
301 2020), a finding further supported by our study; such a link may explain the efficacy of
302 antihistamines in alleviating tinnitus symptoms for some patients. Further, tinnitus may lead to
303 anxiety and depression, and therefore, the use of anxiolytics and antidepressants in our study
304 population was anticipated.

305
306 There was an association with type of medication used and demographic variables such as age,
307 duration of tinnitus, work type, education and ethnicity. Additional results related to the
308 association between medication class among those reporting higher levels of tinnitus severity,
309 anxiety, depression, and insomnia. As anticipated, antidepressants and anxiolytics (i.e., anti-
310 anxiety) use was higher among those with higher anxiety and depression. In addition, anxiolytic

311 drugs were also more commonly used by individuals with higher tinnitus severity and insomnia.
312 While some antibiotics and cancer drugs are known to cause severe and irreversible hearing
313 problems, certain common long-term medication use has also been associated with tinnitus.
314 These common medications include some non-steroidal anti-inflammatory drugs (analgesics),
315 loop diuretics (cardiovascular agents), tricyclic antidepressants and selective serotonin reuptake
316 inhibitor antidepressants (Bisht & Bist, 2011). While our study did not aim to assess the
317 contribution of long-term medication use on tinnitus onset and severity, this is an important
318 question that needs to be evaluated in prospective studies.

319

320 **Study Limitations and Future Directions**

321 There are some limitations that need to be considered during result interpretation. Firstly, the
322 study represents the medication use of individuals with tinnitus who were seeking help for their
323 tinnitus via an internet-based psychological interventions. This may have resulted in some
324 sampling bias as is the participants may not be representative of the general tinnitus population
325 Secondly, there may be some recall bias when reporting the medication, although this may have
326 been reduced as people were completing the questionnaire via the internet at home and thus most
327 likely having access to their medications to crosscheck Thirdly, the current study is cross-
328 sectional study and as a result the longitudinal changes in medication use were not considered.
329 For these reasons, the study results should be interpreted cautiously and be considered as
330 preliminary. Future studies should aim to compare medication profile of individuals with tinnitus
331 to medication use of a comparable age and gender matched general population.

332

333 **Conclusion**

334 This study provides information regarding the medication use by individuals with tinnitus who
335 are seeking psychological intervention. Healthcare professionals should be mindful of the
336 medications that may be used and be prepared to investigate the general health of individuals
337 relying on such medications. Audiologists and their patients may benefit from a careful review of
338 such medications' use and potential side effects. Future studies need to evaluate the effect of
339 these medications on tinnitus. Prospective studies investigating the effect of acute medication use
340 in the past and long-term medication use over time as a cause of tinnitus or a factor increasing
341 the severity of tinnitus are recommended.

342

343 **Funding**

344 This work is funded by the National Institute on Deafness and Communication Disorders
345 (NIDCD) of the National Institute of Health (NIH) under the award number R21DC017214.
346 Funding agency did not have any role in the design or execution of the study.

347

348 **Conflict of Interest**

349 None to declare.

350

351 **Data Sharing**

352 The data that support the findings of this study are available from the corresponding author upon
353 reasonable request.

354 **References**

355 Andersson, G. & Westin, V. (2008). Understanding tinnitus distress: Introducing the concepts of
356 moderators and mediators. *International Journal of Audiology*, 47(Suppl. 2), S106–S111.

357 <https://doi.org/10.1080/14992020802301670>

358

359 Baldo, P., Doree, C., Molin, P., McFerran, D., & Cecco, S. (2012). Antidepressants for patients
360 with tinnitus. *The Cochrane Database of Systematic Reviews*, 2012(9), CD003853.

361 <https://doi.org/10.1002/14651858.CD003853.pub3>

362

363 Bastien, C. H., Vallières, A., & Morin, C. M. (2001). Validation of the Insomnia Severity Index
364 as an outcome measure for insomnia research. *Sleep Medicine*, 2(4), 297–307.

365 [https://doi.org/10.1016/s1389-9457\(00\)00065-4](https://doi.org/10.1016/s1389-9457(00)00065-4)

366

367 Beukes, E.W., Aronson, E.P., Andersson, G., Fagelson, M.A., Munoz, M.F., & Manchaiah, V.
368 (In press). Internet-based Cognitive Behavioral Therapy for tinnitus in the United States: A pilot
369 trial. *American Journal of Audiology*.

370

371 Beukes, E. W., Andersson, G., Fagelson, M. A., & Manchaiah, V. (In press). Internet-based
372 audiologist-guided cognitive behavioral therapy tinnitus in the United States: A randomized
373 controlled trial. *Journal of Medical Internet Research*. <https://preprints.jmir.org/preprint/27584>

374

375 Beukes, E. W., Baguley, D. M., Jacquemin, L., Lourenco, M., Allen, P. M., Onozuka, J.,

376 Stockdale, D., Kaldo, V., Andersson, G., & Manchaiah, V. (2020). Changes in Tinnitus

- 377 Experiences During the COVID-19 Pandemic. *Frontiers in Public Health*, 8, 592878.
378 <https://doi.org/10.3389/fpubh.2020.592878>
379
- 380 Beukes, E. W., Andersson, G., Fagelson, M. A., & Manchaiah, V. (2021c). Dismantling internet-
381 based cognitive behavioral therapy for tinnitus. The contribution of applied relaxation: A
382 randomized controlled trial. *Internet Interventions*, 25, 100402.
383 <https://doi.org/10.1016/j.invent.2021.100402>
384
- 385 Bhatt, J. M., Lin, H. W., & Bhattacharyya, N. (2016). Prevalence, Severity, Exposures, and
386 Treatment Patterns of Tinnitus in the United States. *Journal of the American Medical*
387 *Association Otolaryngology-- Head & Neck Surgery*, 142(10), 959–965.
388 <https://doi.org/10.1001/jamaoto.2016.1700>
389
- 390 Bisht, M., & Bist, S. S. (2011). Ototoxicity: The hidden menace. *Indian Journal of*
391 *Otolaryngology and Head and Neck Surgery: Official Publication of the Association of*
392 *Otolaryngologists of India*, 63(3), 255–259. <https://doi.org/10.1007/s12070-011-0151-8>
393
- 394 Cronlein, T., Geisler, P., & Hajak, G. (2011). Tinnitus and Sleep. In: A.R. Møller, B. Languth,
395 D. DeRidder, & T. Kleinjung (Eds.), *Textbook of Tinnitus* (pp. 505-510). Springer, New York.
396 <https://doi.org/10.1007/978-1-60761-145-5>
397
- 398 Davis, A., & Refaie, A. E. (2020). The epidemiology of tinnitus. In R. Tyler (Ed.), *The*
399 *Handbook of Tinnitus* (pp. 1–23). Singular.

400

401 Drieling, R. L., LaCroix, A. Z., Beresford, S. A., Boudreau, D. M., Kooperberg, C., & Heckbert,
402 S. R. (2016). Validity of self-reported medication use compared with pharmacy records in a
403 cohort of older women: Findings from the women's health initiative. *American Journal of*
404 *Epidemiology*, 184(3), 233–238. <https://doi.org/10.1093/aje/kwv446>

405

406 Fujita, M., Sato, Y., Nagashima, K., Takahashi, S., & Hata, A. (2015). Validity assessment of
407 self-reported medication use by comparing to pharmacy insurance claims. *BMJ Open*, 5(11),
408 e009490. <https://doi.org/10.1136/bmjopen-2015-009490>

409

410 Ganesan, P., Schmiedge, J., Manchaiah, V., Swapna, S., Dhandayutham, S., & Kothandaraman,
411 P. P. (2018). Ototoxicity: A Challenge in Diagnosis and Treatment. *Journal of Audiology &*
412 *Otology*, 22(2), 59–68. <https://doi.org/10.7874/jao.2017.00360>

413

414 Hoang, J. M., Upadhyay, N., Dike, D. N., Lee, J., Johnson, M. L., Cleeland, C. S., Mendoza, T.,
415 Chen, H., & Trivedi, M. V. (2020). Patient-reported outcomes in light of supportive medications
416 in treatment-naïve lung cancer patients. *Supportive Care in Cancer: Official Journal of the*
417 *Multinational Association of Supportive Care in Cancer*, 28(4), 1809–1816.
418 <https://doi.org/10.1007/s00520-019-05004-8>

419

420 Juszczak, H. M., & Loftus, P. A. (2020). Role of allergy in eustachian tube dysfunction. *Current*
421 *Allergy and Asthma Reports*, 20(10), 54. <https://doi.org/10.1007/s11882-020-00951-3>

422

- 423 Kantor, E. D., Rehm, C. D., Du, M., White, E., & Giovannucci, E. L. (2016). Trends in Dietary
424 Supplement Use Among US Adults From 1999-2012. *Journal of the American Medical*
425 *Association*, 316(14), 1464–1474. <https://doi.org/10.1001/jama.2016.14403>
426
- 427 Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ-9: Validity of a brief depression
428 severity measure. *Journal of General Internal Medicine*, 16(9), 606–613.
429 <https://doi.org/10.1046/j.1525-1497.2001.016009606.x>
430
- 431 Langguth, B., Elgoyhen, A. B., & Cederroth, C. R. (2019). Therapeutic Approaches to the
432 Treatment of Tinnitus. *Annual Review of Pharmacology and Toxicology*, 59, 291–313.
433 <https://doi.org/10.1146/annurev-pharmtox-010818-021556>
434
- 435 Lie, J. D., Tu, K. N., Shen, D. D., & Wong, B. M. (2015). Pharmacological Treatment of
436 Insomnia. *P & T : a peer-reviewed journal for formulary management*, 40(11), 759–771.
437
- 438 Manchaiah, V., Valescu, G., Varadaraj, S., Aronson, E. P., Fagelson, M. A., Munoz, M. F.,
439 Andersson, G. & Beukes, E.W. (2020). Features, functionality, and acceptability of Internet-
440 based cognitive behavioral therapy for tinnitus in the United States. *American Journal of*
441 *Audiology*, 29(3), 476-490. https://doi.org/10.1044/2020_AJA-20-00002
442
- 443 Martin, C. B., Hales, C. M., Gu, Q., & Ogden, C. L. (2019). *Prescription drug use in the United*
444 *States, 2015–2016. NCHS Data Brief, no 334*. Center for Disease Control and Prevention.
445 <https://www.cdc.gov/nchs/products/databriefs/db334.htm>

446
447 McCormack, A., Edmondson-Jones, M., Somerset, S., & Hall, D. (2016). A systematic review of
448 the reporting of tinnitus prevalence and severity. *Hearing Research*, 337, 70-79.
449 <https://doi.org/10.1016/j.heares.2016.05.009>

450
451 Meikle, M. B., Henry, J. A., Griest, S. E., Stewart, B. J., Abrams, H. B., McArdle, R., Myers, P.
452 J., Newman, C. W., Sandridge, S., Turk, D. C., Folmer, R. L., Frederick, E. J., House, J. W.,
453 Jacobson, G. P., Kinney, S. E., Martin, W. H., Nagler, S. M., Reich, G. E., Searchfield, G., ...
454 Vernon, J. A. (2012). The tinnitus functional index: development of a new clinical measure for
455 chronic, intrusive tinnitus. *Ear and Hearing*, 33(2), 153–176.
456 <https://doi.org/10.1097/AUD.0b013e31822f67c0>

457
458 Qato, D. M., Alexander, G. C., Conti, R. M., Johnson, M., Schumm, P., & Lindau, S. T. (2008).
459 Use of prescription and over-the-counter medications and dietary supplements among older
460 adults in the United States. *Journal of the American Medical Association*, 300(24), 2867–2878.
461 <https://doi.org/10.1001/jama.2008.892>

462
463 Qato, D. M., Wilder, J., Schumm, L. P., Gillet, V., & Alexander, G. C. (2016). Changes in
464 prescription and over-the-counter medication and dietary supplement use among older adults in
465 the United States, 2005 vs 2011. *Journal of the American Medical Association Internal*
466 *Medicine*, 176(4), 473–482. <https://doi.org/10.1001/jamainternmed.2015.8581>

467

- 468 Rabin, R., & de Charro, F. (2001). EQ-5D: a measure of health status from the EuroQol
469 Group. *Annals of Medicine*, 33(5), 337–343. <https://doi.org/10.3109/07853890109002087>
- 470 Rizk, H. G., Lee, J. A., Liu, Y. F., Endriukaitis, L., Isaac, J. L., & Bullington, W. M. (2020).
471 Drug-Induced Ototoxicity: A Comprehensive Review and Reference Guide. *Pharmacotherapy*,
472 40(12), 1265-1275. <https://doi.org/10.1002/phar.2478>
- 473
- 474 Rock C. L. (2007). Multivitamin-multimineral supplements: Who uses them? *The American*
475 *Journal of Clinical Nutrition*, 85(1), 277S–279S. <https://doi.org/10.1093/ajcn/85.1.277S>
- 476
- 477 Salazar, J. W., Meisel, K., Smith, E. R., Quiggle, A., McCoy, D. B., & Amans, M. R. (2019).
478 Depression in Patients with Tinnitus: A Systematic Review. *Otolaryngology--Head and Neck*
479 *Surgery: Official Journal of American Academy of Otolaryngology-Head and Neck*
480 *Surgery*, 161(1), 28–35. <https://doi.org/10.1177/0194599819835178>
- 481
- 482 Spitzer, R. L., Kroenke, K., Williams, J. B. W., Lowe, B. (2006). A brief measure for assessing
483 generalized anxiety disorder. *Archives of Internal Medicine*, 166(10), 1092-1097.
484 <https://doi.org/10.1001/archinte.166.10.1092>
- 485
- 486 Trick, L., Watkins, E., Windeatt, S., & Dickens, C. (2016). The association of perseverative
487 negative thinking with depression, anxiety and emotional distress in people with long term
488 conditions: A systematic review. *Journal of Psychosomatic Research*, 91, 89–101.
489 <https://doi.org/10.1016/j.jpsychores.2016.11.004>
- 490

491 United States Pharmacopeial Convention (2017). *USP Medicare Model Guidelines*. Retrieved
492 May 29, 2019, from <https://www.usp.org/health-quality-safety/usp-medicare-model-guidelines>
493
494 West, S. L., Savitz, D. A., Koch, G., et al. (1995). Recall accuracy for prescription medications:
495 Self-report compared with database information. *American Journal of Epidemiology*, *142*(10),
496 1103–1112. <https://doi.org/10.1093/oxfordjournals.aje.a117563>.
497